Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Häuser W[au]:

EULAR revised recommendations for the management of fibromyalgia. Macfarlane GJ et al. Ann Rheum Dis. (2017)

Fibromyalgia. Häuser W et al. Nat Rev Dis Primers. (2015)

Facts and myths pertaining to fibromyalgia. Häuser W et al. Dialogues Clin Neurosci. (2018)

Search results

Items: 1 to 50 of 800

1.

2016 modified American College of Rheumatology fibromyalgia criteria, ACTTION-APS Pain Taxonomy criteria and the prevalence of fibromyalgia.

Häuser W, Brähler E, Ablin J, Wolfe F.

Arthritis Care Res (Hoboken). 2020 Apr 5. doi: 10.1002/acr.24202. [Epub ahead of print]

PMID:
32248629
2.

Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status.

Salaffi F, Di Carlo M, Farah S, Atzeni F, Buskila D, Ablin JN, Häuser W, Sarzi-Puttini P.

Rheumatology (Oxford). 2020 Mar 24. pii: keaa061. doi: 10.1093/rheumatology/keaa061. [Epub ahead of print]

PMID:
32206792
3.

All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia.

Wolfe F, Ablin J, Baker JF, Diab R, Guymer EK, Littlejohn GO, Michaud K, Rasker JJ, Walitt B, Häuser W.

Semin Arthritis Rheum. 2020 Feb 16. pii: S0049-0172(20)30028-7. doi: 10.1016/j.semarthrit.2020.02.005. [Epub ahead of print]

PMID:
32173059
4.

Validation of the German version of the Bodily Distress Syndrome 25 checklist in a representative German population sample.

Schmalbach B, Roenneberg C, Hausteiner-Wiehle C, Henningsen P, Brähler E, Zenger M, Häuser W.

J Psychosom Res. 2020 Mar 3;132:109991. doi: 10.1016/j.jpsychores.2020.109991. [Epub ahead of print]

PMID:
32160574
5.

A cautious hope for cannabidiol (CBD) in rheumatology care.

Fitzcharles MA, Clauw DJ, Hauser W.

Arthritis Care Res (Hoboken). 2020 Mar 7. doi: 10.1002/acr.24176. [Epub ahead of print] Review.

PMID:
32144889
6.

[The US opioid epidemic is threatening Germany].

Häuser W, Petzke F, Radbruch L.

Schmerz. 2020 Feb;34(1):1-3. doi: 10.1007/s00482-019-00441-0. German. No abstract available.

PMID:
32076850
7.

Taxonomies for chronic visceral pain.

Häuser W, Baranowski A, Messelink B, Wesselmann U.

Pain. 2020 Feb 5. doi: 10.1097/j.pain.0000000000001825. [Epub ahead of print] No abstract available.

PMID:
32032194
8.
9.

Opioids for chronic low back pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks of double-blind duration.

Petzke F, Klose P, Welsch P, Sommer C, Häuser W.

Eur J Pain. 2020 Mar;24(3):497-517. doi: 10.1002/ejp.1519. Epub 2019 Dec 27. Review.

PMID:
31823442
10.

The Problematic Nature of Fibromyalgia Diagnosis in the Community.

Srinivasan S, Maloney E, Wright B, Kennedy M, Kallail KJ, Rasker JJ, Häuser W, Wolfe F.

ACR Open Rheumatol. 2019 Mar 15;1(1):43-51. doi: 10.1002/acr2.1006. eCollection 2019 Mar.

11.

In Reply.

Häuser W, Layer P.

Dtsch Arztebl Int. 2019 Nov 1;116(44):755-756. doi: 10.3238/arztebl.2019.0755c. No abstract available.

12.

Acute Abdomen in Chronic Anorexia Nervosa with Episodes of Bulimia.

Hartleb A, Geser L, Häuser W.

Dtsch Arztebl Int. 2019 Oct 25;116(43):735. doi: 10.3238/arztebl.2019.0735. No abstract available.

13.
14.

Psychological therapies for chronic widespread pain and fibromyalgia syndrome.

Häuser W, Jones G.

Best Pract Res Clin Rheumatol. 2019 Jun;33(3):101416. doi: 10.1016/j.berh.2019.05.001. Epub 2019 May 31. Review.

PMID:
31703789
15.

Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: Systematic review and meta-analysis of open-label extension trials with a study duration ≥26 weeks.

Bialas P, Maier C, Klose P, Häuser W.

Eur J Pain. 2020 Feb;24(2):265-278. doi: 10.1002/ejp.1496. Epub 2019 Nov 14. Review.

PMID:
31661587
16.

Cannabinoids in the treatment of rheumatic diseases: Pros and cons.

Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, Häuser W.

Autoimmun Rev. 2019 Dec;18(12):102409. doi: 10.1016/j.autrev.2019.102409. Epub 2019 Oct 21. Review.

PMID:
31648042
17.

Fibromyalgia as a chronic primary pain syndrome: issues to discuss.

Häuser W, Clauw D, Fitzcharles MA.

Pain. 2019 Nov;160(11):2651-2652. doi: 10.1097/j.pain.0000000000001686. No abstract available.

PMID:
31626074
18.

Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria.

Wolfe F, Butler SH, Fitzcharles M, Häuser W, Katz RL, Mease PJ, Rasker JJ, Russell AS, Russell IJ, Walitt B.

Scand J Pain. 2019 Dec 18;20(1):77-86. doi: 10.1515/sjpain-2019-0054.

PMID:
31596726
19.

[Cannabis].

Cremer-Schaeffer P, Häuser W.

Schmerz. 2019 Oct;33(5):375-377. doi: 10.1007/s00482-019-00396-2. German. No abstract available.

PMID:
31571059
20.

[Position paper on medical cannabis and cannabis-based medicines in pain medicine].

Petzke F, Karst M, Gastmeier K, Radbruch L, Steffen E, Häuser W; Ad-hoc-Kommission der Deutschen Schmerzgesellschaft „Cannabis in der Medizin“.

Schmerz. 2019 Oct;33(5):449-465. doi: 10.1007/s00482-019-00407-2. Review. German.

PMID:
31541311
21.

[Erratum to: Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety].

Bialas P, Drescher B, Gottschling S, Juckenhöfel S, Konietzke D, Kuntz W, Kühne-Adler I, Merl-Ripplinger H, Preisegger D, Schneider K, Strauß M, Welsch P, Häuser W.

Schmerz. 2019 Oct;33(5):407. doi: 10.1007/s00482-019-00403-6. German. No abstract available.

PMID:
31529238
22.

Medical cannabis and cannabinoids in rheumatology: where are we now?

Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, Marotto D, Ceribelli A, Ablin JN, Hauser W.

Expert Rev Clin Immunol. 2019 Oct;15(10):1019-1032. doi: 10.1080/1744666X.2019.1665997.

PMID:
31512536
23.

[Medicinal cannabis and cannabis-based medication: an appeal to physicians, journalists, health insurances, and politicians for their responsible handling].

Häuser W, Hoch E, Petzke F, Thomasius R, Radbruch L, Batra A, Sommer C, Havemann-Reinecke U.

Schmerz. 2019 Oct;33(5):466-470. doi: 10.1007/s00482-019-00409-0. German.

PMID:
31478143
24.

A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models.

Montgomery MA, Ramos M, Kelvin EA, Carpio A, Jaramillo A, Hauser WA, Zhang H.

Trans R Soc Trop Med Hyg. 2019 Dec 1;113(12):781-788. doi: 10.1093/trstmh/trz073.

PMID:
31433058
25.

The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome.

Häuser W, Marschall U, Layer P, Grobe T.

Dtsch Arztebl Int. 2019 Jul 8;116(27-28):463-470. doi: 10.3238/arztebl.2019.0463.

26.

Medical cannabis: strengthening evidence in the face of hype and public pressure.

Fitzcharles MA, Shir Y, Häuser W.

CMAJ. 2019 Aug 19;191(33):E907-E908. doi: 10.1503/cmaj.190509. No abstract available.

27.

Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.

Carpio A, Chang M, Zhang H, Romo ML, Jaramillo A, Hauser WA, Kelvin EA.

Epilepsia. 2019 Sep;60(9):1820-1828. doi: 10.1111/epi.16302. Epub 2019 Jul 29.

PMID:
31355931
28.

Chronic primary pain: a pain-centered view of the world is too narrow.

Henningsen P, Layer P, Fink P, Häuser W.

Pain. 2019 Jul;160(7):1683. doi: 10.1097/j.pain.0000000000001563. No abstract available.

PMID:
31219954
29.

[Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].

Bialas P, Drescher B, Gottschling S, Juckenhöfel S, Konietzke D, Kuntz W, Kühne-Adler I, Merl-Ripplinger H, Preisegger D, Schneider K, Strauß M, Welsch P, Häuser W.

Schmerz. 2019 Oct;33(5):399-406. doi: 10.1007/s00482-019-0383-1. Review. German. Erratum in: Schmerz. 2019 Sep 16;:.

PMID:
31201550
30.

[Evidence of the efficacy and safety of cannabis medicines for chronic pain management : A methodological minefield].

Häuser W, Petzke F.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Jul;62(7):836-844. doi: 10.1007/s00103-019-02966-2. Review. German.

PMID:
31139839
31.

Meta-analysis of Opioids for Chronic Pain.

Häuser W, Tölle T, Moore A.

JAMA. 2019 May 21;321(19):1934-1935. doi: 10.1001/jama.2019.2177. No abstract available.

PMID:
31112253
32.

Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.

Häuser W, Welsch P, Klose P, Radbruch L, Fitzcharles MA.

Schmerz. 2019 Oct;33(5):424-436. doi: 10.1007/s00482-019-0373-3.

PMID:
31073761
33.

[Cannabis-based drugs : Don't pit clinical experience and systematic reviews against each other].

Schmelz M, Häuser W, Hoch E, Petzke F, Sommer C.

Schmerz. 2019 Apr;33(2):97-99. doi: 10.1007/s00482-018-0349-8. German. No abstract available.

PMID:
30949833
34.

An unparalleled assessment of the global burden of epilepsy.

Hauser WA.

Lancet Neurol. 2019 Apr;18(4):322-324. doi: 10.1016/S1474-4422(19)30042-0. Epub 2019 Feb 14. No abstract available.

35.

Fibromyalgia syndrome: under-, over- and misdiagnosis.

Häuser W, Sarzi-Puttini P, Fitzcharles MA.

Clin Exp Rheumatol. 2019 Jan-Feb;37 Suppl 116(1):90-97. Epub 2019 Feb 8. Review.

36.

Diagnosis of Fibromyalgia: Disagreement Between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic.

Wolfe F, Schmukler J, Jamal S, Castrejon I, Gibson KA, Srinivasan S, Häuser W, Pincus T.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):343-351. doi: 10.1002/acr.23731. Epub 2019 Feb 6.

37.

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.

Fitzcharles MA, Niaki OZ, Hauser W, Hazlewood G; Canadian Rheumatology Association.

J Rheumatol. 2019 May;46(5):532-538. doi: 10.3899/jrheum.181120. Epub 2019 Jan 15.

PMID:
30647183
38.

Obesity, depression and hip pain.

Schwarze M, Häuser W, Schmutzer G, Brähler E, Beckmann NA, Schiltenwolf M.

Musculoskeletal Care. 2019 Mar;17(1):126-132. doi: 10.1002/msc.1380. Epub 2019 Jan 8.

PMID:
30623588
39.

Medical Cannabis for Older Patients.

Minerbi A, Häuser W, Fitzcharles MA.

Drugs Aging. 2019 Jan;36(1):39-51. doi: 10.1007/s40266-018-0616-5. Review.

PMID:
30488174
40.

Systematic review and meta-analysis on non-opioid analgesics in palliative medicine.

Schüchen RH, Mücke M, Marinova M, Kravchenko D, Häuser W, Radbruch L, Conrad R.

J Cachexia Sarcopenia Muscle. 2018 Dec;9(7):1235-1254. doi: 10.1002/jcsm.12352. Epub 2018 Oct 29.

41.

Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse.

Häuser W, Schubert T, Scherbaum N, Tölle T.

Schmerz. 2018 Oct 16. doi: 10.1007/s00482-018-0331-5. [Epub ahead of print]

PMID:
30327867
42.

The association of adverse childhood experiences and of resilience with chronic noncancer pain in the German adult population - A cross-sectional survey.

Häuser W, Brähler E, Schmutzer G, Glaesmer H.

Eur J Pain. 2019 Mar;23(3):555-564. doi: 10.1002/ejp.1329. Epub 2018 Oct 31.

PMID:
30318676
43.

[A weakly negative recommendation is not an absolute "no" : Comment on AWMF guideline recommendations for cannabis-based medicines in fibromyalgia syndrome].

Häuser W, Petzke F, Nothacker M.

Schmerz. 2018 Oct;32(5):327-329. doi: 10.1007/s00482-018-0328-0. German. No abstract available.

PMID:
30259150
44.

[Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse].

Häuser W, Schubert T, Scherbaum N, Tölle T.

Schmerz. 2018 Dec;32(6):419-426. doi: 10.1007/s00482-018-0324-4. German.

PMID:
30242530
45.

[Errors and Solutions During Medical Therapy for Chronic Pain].

Häuser W, Schuler M.

Dtsch Med Wochenschr. 2018 Sep;143(19):1381-1388. doi: 10.1055/s-0044-102229. Epub 2018 Sep 19. Review. German.

PMID:
30231285
46.

Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias.

Wolfe F, Walitt B, Perrot S, Rasker JJ, Häuser W.

PLoS One. 2018 Sep 13;13(9):e0203755. doi: 10.1371/journal.pone.0203755. eCollection 2018.

47.

Quality of Life of Celiac Patients in Brazil: Questionnaire Translation, Cultural Adaptation and Validation.

Pratesi CP, Häuser W, Uenishi RH, Selleski N, Nakano EY, Gandolfi L, Pratesi R, Zandonadi RP.

Nutrients. 2018 Aug 25;10(9). pii: E1167. doi: 10.3390/nu10091167.

48.

Mirtazapine for fibromyalgia in adults.

Welsch P, Bernardy K, Derry S, Moore RA, Häuser W.

Cochrane Database Syst Rev. 2018 Aug 6;8:CD012708. doi: 10.1002/14651858.CD012708.pub2. Review.

49.

European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management.

Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, Perrot S, Schäfer M, Wells C, Brill S.

Eur J Pain. 2018 Oct;22(9):1547-1564. doi: 10.1002/ejp.1297. Epub 2018 Sep 4.

PMID:
30074291
50.

Primary and Secondary Fibromyalgia Are The Same: The Universality of Polysymptomatic Distress.

Wolfe F, Walitt B, Rasker JJ, Häuser W.

J Rheumatol. 2019 Feb;46(2):204-212. doi: 10.3899/jrheum.180083. Epub 2018 Jul 15.

PMID:
30008459

Supplemental Content

Loading ...
Support Center